Designing Effective Antibody-Drug Conjugates: What Have We Learned in Forty Years & What Are the Future Prospects

Time: 9:40 am
day: Day One


  • Effective exploitation of antibodies for treating cancer required many lessons to be learned and technologies to be developed in the 1980s and 1990s
  • Since Mylotarg’s approval in 2000, major advances in antibody-drug conjugate technologies were pioneered by ImmunoGen, Inc., and Seattle Genetics, leading to the approvals of Kadcyla and Adcetris
  • With many “tools in the toolbox”, development of ADCs for cancer treatment has a promising future